NASDAQ:CYTK - Cytokinetics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$8.40 +0.20 (+2.44 %)
(As of 06/25/2018 04:00 AM ET)
Previous Close$8.20
Today's Range$8.05 - $8.60
52-Week Range$6.75 - $15.95
Volume969,977 shs
Average Volume435,376 shs
Market Capitalization$444.42 million
P/E Ratio-3.24
Dividend YieldN/A
Beta1.17
Cytokinetics logoCytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in phase III clinical trials in patients with heart failure; and reldesemtiv, a fast skeletal muscle activator, which is in two phase II clinical trials in patients with spinal muscular atrophy and amyotrophic lateral sclerosis. It also develops reldesemtiv that is in phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in phase Ib clinical trials in elderly subjects with limited mobility. The company has strategic alliances with Astellas Pharma Inc. and Amgen Inc. The company was founded in 1997 and is headquartered in South San Francisco, California.

Receive CYTK News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CYTK
CUSIPN/A
Phone650-624-3000

Debt

Debt-to-Equity Ratio0.32
Current Ratio7.07
Quick Ratio7.07

Price-To-Earnings

Trailing P/E Ratio-3.24
Forward P/E Ratio-4.22
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.37 million
Price / Sales34.05
Cash FlowN/A
Price / CashN/A
Book Value$2.04 per share
Price / Book4.12

Profitability

EPS (Most Recent Fiscal Year)($2.59)
Net Income$-127,790,000.00
Net Margins-172.27%
Return on Equity-99.50%
Return on Assets-42.59%

Miscellaneous

Employees137
Outstanding Shares54,200,000

The Truth About Cryptocurrencies

Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

How were Cytokinetics' earnings last quarter?

Cytokinetics (NASDAQ:CYTK) posted its quarterly earnings data on Thursday, April, 26th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.50) by $0.06. The biopharmaceutical company earned $5.27 million during the quarter, compared to analysts' expectations of $5.50 million. Cytokinetics had a negative return on equity of 99.50% and a negative net margin of 172.27%. View Cytokinetics' Earnings History.

When is Cytokinetics' next earnings date?

Cytokinetics is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Cytokinetics.

What price target have analysts set for CYTK?

8 brokerages have issued 1-year target prices for Cytokinetics' stock. Their predictions range from $10.00 to $24.00. On average, they expect Cytokinetics' stock price to reach $15.6250 in the next year. View Analyst Ratings for Cytokinetics.

What are Wall Street analysts saying about Cytokinetics stock?

Here are some recent quotes from research analysts about Cytokinetics stock:
  • 1. Cantor Fitzgerald analysts commented, "Reldesemtiv and omecamtiv mecarbil, CYTK’s lead programs, have sizable opportunities given the limited treatment options in the markets that are being explored but are novel mechanisms, which enhances the risk profile, in our view. The loss of tirasemtiv was a sizable blow to CYTK and new data for reldesemtiv are a plus, in our view, with the shares now essentially at our price target." (6/17/2018)
  • 2. According to Zacks Investment Research, "Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. " (8/17/2017)
  • 3. Cowen Inc analysts commented, "CYTK reported a Q2 loss of $29.1MM and ended the quarter with $332MM in cash." (8/4/2017)

Who are some of Cytokinetics' key competitors?

Who are Cytokinetics' key executives?

Cytokinetics' management team includes the folowing people:
  • Mr. Robert I. Blum, CEO, Pres & Director (Age 54)
  • Mr. Ching W. Jaw, Sr. VP & CFO (Age 55)
  • Dr. Andrew A. Wolff, Sr. VP & Chief Medical Officer (Age 63)
  • Dr. Fady Ibraham Malik, Exec. VP of R&D (Age 54)
  • Dr. Bradley Paul Morgan, Sr. VP of Research & Non-Clinical Devel. (Age 58)

Has Cytokinetics been receiving favorable news coverage?

Press coverage about CYTK stock has trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cytokinetics earned a daily sentiment score of 0.19 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 46.27 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (13.44%), Wasatch Advisors Inc. (3.26%), Pinnacle Associates Ltd. (1.64%), Citigroup Inc. (1.43%), Principal Financial Group Inc. (0.73%) and Principal Financial Group Inc. (0.74%). Company insiders that own Cytokinetics stock include Bradley Paul Morgan, Caryn Gordon Mcdowell, Fady Ibraham Malik, Robert I Blum and Santo J Costa. View Institutional Ownership Trends for Cytokinetics.

Which major investors are selling Cytokinetics stock?

CYTK stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., Dimensional Fund Advisors LP, Schwab Charles Investment Management Inc. and American International Group Inc.. Company insiders that have sold Cytokinetics company stock in the last year include Bradley Paul Morgan, Caryn Gordon Mcdowell, Fady Ibraham Malik, Robert I Blum and Santo J Costa. View Insider Buying and Selling for Cytokinetics.

Which major investors are buying Cytokinetics stock?

CYTK stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Millennium Management LLC, Employees Retirement System of Texas, A.R.T. Advisors LLC, UBS Group AG, JPMorgan Chase & Co., BlackRock Inc. and DRW Securities LLC. View Insider Buying and Selling for Cytokinetics.

How do I buy shares of Cytokinetics?

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $8.40.

How big of a company is Cytokinetics?

Cytokinetics has a market capitalization of $444.42 million and generates $13.37 million in revenue each year. The biopharmaceutical company earns $-127,790,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. Cytokinetics employs 137 workers across the globe.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]


MarketBeat Community Rating for Cytokinetics (CYTK)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  429 (Vote Outperform)
Underperform Votes:  139 (Vote Underperform)
Total Votes:  568
MarketBeat's community ratings are surveys of what our community members think about Cytokinetics and other stocks. Vote "Outperform" if you believe CYTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.